EE397 Budget Impact Analysis of Nivolumab Plus Ipilimumab for the Management of Advanced Unresected Malignant Pleural Mesothelioma (MPM)
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.698
https://www.valueinhealthjournal.com/article/S1098-3015(23)00798-2/fulltext
Title :
EE397 Budget Impact Analysis of Nivolumab Plus Ipilimumab for the Management of Advanced Unresected Malignant Pleural Mesothelioma (MPM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00798-2&doi=10.1016/j.jval.2023.03.698
First page :
Section Title :
Open access? :
No
Section Order :
10178